Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 280 | $245.00 | $68,600.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,078 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $245.00 (range $244.52 to $245.43.) Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 202 | $243.85 | $49,257.70 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,358 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.85 (range $243.52 to $244.29). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 640 | $242.80 | $155,392.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,560 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.80 (range $242.45 to $243.32). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 240 | $241.95 | $58,068.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.95 (range $241.43 to $242.40). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 145 | $245.75 | $35,633.75 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,070 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.54 to $245.85). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 286 | $244.99 | $70,067.14 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,215 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.52 to $245.30). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 160 | $243.78 | $39,004.80 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,501 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.78 (range $243.42 to $244.23). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 528 | $242.78 | $128,187.84 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,661 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.38 to $243.31). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 160 | $241.82 | $38,691.20 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,189 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.82 (range $241.33 to $242.18). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:31 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 2,496 | $241.50 | $602,784.00 |
DisclosureSEC source: 0001209191-20-010534 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,474 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:32 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 2,496 | $241.50 | $602,784.00 |
DisclosureSEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,839 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:33 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
Tax withholdingCommon Stock | 944 | $241.50 | $227,976.00 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,341 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:35 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Tax withholdingCommon Stock | 9,314 | $241.50 | $2,249,331.00 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,226 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:36 UTC |
Parini MichaelEVP, CL&AO
|
Tax withholdingCommon Stock | 2,496 | $241.50 | $602,784.00 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,410 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:37 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 3,262 | $241.50 | $787,773.00 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,936 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:38 UTC |
Silva Paul MSVP & Controller
|
Tax withholdingCommon Stock | 1,248 | $241.50 | $301,392.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,440 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
Tax withholdingCommon Stock | 597 | $241.50 | $144,175.50 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,349 Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,200 | $248.50 | $298,200.00 |
DisclosureSEC source: 0001209191-20-008865 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,970 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.50 (range $248.37 to $248.82). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,235 | $247.73 | $553,676.55 |
DisclosureSEC source: 0001209191-20-008865 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,170 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.36 to $248.28). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,472 | $246.73 | $856,646.56 |
DisclosureSEC source: 0001209191-20-008865 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,405 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.73 (range $246.29 to $247.26). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 5,725 | $245.81 | $1,407,262.25 |
DisclosureSEC source: 0001209191-20-008865 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,877 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.81 (range $245.29 to $246.24). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,400 | $244.89 | $832,626.00 |
DisclosureSEC source: 0001209191-20-008865 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,602 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.89 (range $244.28 to $245.25). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,000 | $243.36 | $243,360.00 |
DisclosureSEC source: 0001209191-20-008865 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,002 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $243.36 (range $242.88 to $243.79). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 486 | $248.62 | $120,829.32 |
DisclosureSEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,335 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.62 (range $248.47 to $248.90). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,863 | $247.91 | $461,856.33 |
DisclosureSEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,821 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.91 (range $247.44 to $248.43). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,770 | $246.76 | $436,765.20 |
DisclosureSEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,684 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.76 (range $246.43 to $247.29). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 3,377 | $245.93 | $830,505.61 |
DisclosureSEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,454 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.93 (range $245.37 to $246.28). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 2,860 | $244.99 | $700,671.40 |
DisclosureSEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,831 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.37 to $245.36). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 930 | $243.76 | $226,696.80 |
DisclosureSEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,691 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.29 to $244.28). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 4,609 | $248.45 | $1,145,106.05 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,540 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.45 (range $248.02 to $248.97). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 7,533 | $247.49 | $1,864,342.17 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,149 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.49 (range $246.92 to $247.88). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 14,433 | $246.27 | $3,554,414.91 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,682 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.27 (range $245.91 to $246.87). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 14,024 | $245.37 | $3,441,068.88 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,115 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.37 (range $244.91 to $245.90). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 4,124 | $244.56 | $1,008,565.44 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,139 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.56 (range $243.91 to $244.90). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 2,800 | $243.37 | $681,436.00 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,263 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $243.37 (range $242.88 to $243.84). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 1,344 | $248.52 | $334,010.88 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,906 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.52 (range $248.23 to $248.93). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 2,499 | $247.62 | $618,802.38 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,250 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.62 (range $247.14 to $248.08). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 3,783 | $246.52 | $932,585.16 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,749 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.52 (range $246.14 to $247.11). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 6,232 | $245.62 | $1,530,703.84 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,532 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.62 (range $245.12 to $246.11). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 2,102 | $244.67 | $514,296.34 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,764 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.67 (range $243.94 to $244.93). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 922 | $243.42 | $224,433.24 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,866 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.42 (range $242.88 to $243.81). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 400 | $248.73 | $99,492.00 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,198 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.73 (range $248.60 to $248.82). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 2,103 | $247.98 | $521,501.94 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,598 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.98 (range $247.55 to $248.50). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,821 | $246.88 | $449,568.48 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,701 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.88 (range $246.53 to $247.39). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 4,320 | $245.99 | $1,062,676.80 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,522 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.99 (range $245.50 to $246.45). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 3,426 | $245.05 | $839,541.30 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,842 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $245.05 (range $244.50 to $245.47). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,000 | $243.53 | $243,530.00 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,268 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.53 (range $242.88 to $243.86). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 1,102 | $247.93 | $273,218.86 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,688 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.93 (range $247.58 to $248.55). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 1,120 | $246.84 | $276,460.80 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,790 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.84 (range $246.46 to $247.38). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 1,700 | $245.89 | $418,013.00 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,910 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.89 (range $245.39 to $246.30). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.